These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8625532)

  • 21. Recombinant antibodies in bioactive peptide design.
    Monfardini C; Kieber-Emmons T; VonFeldt JM; O'Malley B; Rosenbaum H; Godillot AP; Kaushansky K; Brown CB; Voet D; McCallus DE
    J Biol Chem; 1995 Mar; 270(12):6628-38. PubMed ID: 7896802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations.
    Svenson M; Hansen MB; Ross C; Diamant M; Rieneck K; Nielsen H; Bendtzen K
    Blood; 1998 Mar; 91(6):2054-61. PubMed ID: 9490690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disseminated Cryptococcosis Due to Anti-Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies in the Absence of Pulmonary Alveolar Proteinosis.
    Kuo CY; Wang SY; Shih HP; Tu KH; Huang WC; Ding JY; Lin CH; Yeh CF; Ho MW; Chang SC; He CY; Chen HK; Ho CH; Lee CH; Chi CY; Ku CL
    J Clin Immunol; 2017 Feb; 37(2):143-152. PubMed ID: 28013480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of GM-CSF products in cancer patients following immunostimulatory therapy with GM-CSF.
    Wadhwa M; Mellstedt H; Small E; Thorpe R
    Dev Biol (Basel); 2003; 112():61-7. PubMed ID: 12762505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokine refacing effect reduces granulocyte macrophage colony-stimulating factor susceptibility to antibody neutralization.
    Heinzelman P; Carlson SJ; Cox GN
    Protein Eng Des Sel; 2015 Oct; 28(10):461-6. PubMed ID: 25855658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated/extrapulmonary nocardiosis.
    Rosen LB; Rocha Pereira N; Figueiredo C; Fiske LC; Ressner RA; Hong JC; Gregg KS; Henry TL; Pak KJ; Baumgarten KL; Seoane L; Garcia-Diaz J; Olivier KN; Zelazny AM; Holland SM; Browne SK
    Clin Infect Dis; 2015 Apr; 60(7):1017-25. PubMed ID: 25472947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer.
    Rucker R; Bresler HS; Heffelfinger M; Kim JA; Martin EW; Triozzi PL
    J Immunother; 1999 Jan; 22(1):80-4. PubMed ID: 9924703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting granulocyte-macrophage colony-stimulating factor in epithelial and vascular remodeling in experimental eosinophilic esophagitis.
    McNamee EN; Biette KA; Hammer J; Harris R; Miyazawa H; Lee JJ; Furuta GT; Masterson JC
    Allergy; 2017 Aug; 72(8):1232-1242. PubMed ID: 27926989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granulocyte-macrophage colony-stimulating factor after autologous marrow transplantation for Hodgkin's disease.
    Klingemann HG; Wilkie-Boyd K; Rubin A; Onetto N; Nantel SH; Barnett MJ; Reece DE; Shepherd JD; Phillips GL
    Biotechnol Ther; 1994; 5(1-2):1-13. PubMed ID: 7703829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of GM-CSF antagonist peptides.
    VonFeldt JM; Monfardini C; Fish S; Rosenbaum H; Kieber-Emmons T; Williams RM; Khan SA; Weiner DB; Williams WV
    Pept Res; 1995; 8(1):20-7, 30-2. PubMed ID: 7756751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.
    Ragnhammar P; Masucci G; Frödin JE; Hjelm AL; Mellstedt H
    Cancer Immunol Immunother; 1992; 35(3):158-64. PubMed ID: 1638551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors.
    Ragnhammar P
    Med Oncol; 1996 Sep; 13(3):167-76. PubMed ID: 9106176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GM-CSF as a therapeutic target in inflammatory diseases.
    van Nieuwenhuijze A; Koenders M; Roeleveld D; Sleeman MA; van den Berg W; Wicks IP
    Mol Immunol; 2013 Dec; 56(4):675-82. PubMed ID: 23933508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.
    Ragnhammar P; Fagerberg J; Frödin JE; Wersäll P; Hansson LO; Mellstedt H
    Cancer Immunol Immunother; 1995 Jun; 40(6):367-75. PubMed ID: 7627993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.
    Skog AL; Wersäll P; Ragnhammar P; Frödin JE; Mellstedt H
    Cancer Immunol Immunother; 2002 Jul; 51(5):255-62. PubMed ID: 12070712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis c.
    Carreño V; Martín J; Pardo M; Brotons A; Anchía P; Navas S; Fernández M; Arocena C; Quiroga JA
    Cytokine; 2000 Feb; 12(2):165-70. PubMed ID: 10671303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural and therapy-induced anti-GM-CSF and anti-G-CSF antibodies in human serum.
    Revoltella RP; Laricchia-Robbio L; Moscato S; Genua A; Liberati AM
    Leuk Lymphoma; 1997 Dec; 26 Suppl 1():29-34. PubMed ID: 9570677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An immunodominant epitope in a functional domain near the N-terminus of human granulocyte-macrophage colony-stimulating factor identified by cross-reaction of synthetic peptides with neutralizing anti-protein and anti-peptide antibodies.
    Beffy P; Rovero P; Di Bartolo V; Laricchia Robbio L; Dané A; Pegoraro S; Bertolero F; Revoltella RP
    Hybridoma; 1994 Dec; 13(6):457-68. PubMed ID: 7737670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
    Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
    J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.